Open AccessInduction of trismus by sunitinib and pazopanib in metastatic renal cell carcinoma
Author(s) -
Ridhima Iyer,
Bruce Montgomery,
Hardev Pandha
Publication year - 2016
Publication title -
indian journal of urology/indian journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.333
H-Index - 30
eISSN - 1998-3824
pISSN - 0970-1591
DOI - 10.4103/0970-1591.194787
Subject(s) - pazopanib , medicine , sunitinib , renal cell carcinoma , tyrosine kinase inhibitor , tyrosine kinase , oncology , trismus , cancer , surgery , receptor
Tyrosine kinase inhibitors sunitinib and pazopanib are used as first-line agents in the treatment of metastatic renal cell carcinoma. Treatment-related toxicities have been described with both these drugs. This report describes a patient with metastatic renal carcinoma who developed trismus while being treated with these agents and is, to the best of our knowledge, the first such case to be reported.